NCT01383148终止2 期
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- Transgene
- 入组人数
- 222
- 试验地点
- 72
- 主要终点
- Phase 3: Overall Survival (OS)
研究概览
简要总结
This is a Phase IIb/III randomized, double-blind, placebo-controlled study to compare the efficacy and safety of first-line therapy combined with TG4010 or placebo in stage IV non-small cell lung cancer (NSCLC).
TG4010 is a suspension of recombinant Modified Vaccinia virus strain Ankara (MVA strain) carrying coding sequences for human MUC1 antigen and human interleukin-2 (IL2). TG4010 has been developed for use as an immunotherapy in cancer patients whose tumors express the MUC1 antigen.
TG4010 is intended to induce a MUC1-specific cellular immune response and to produce a non-specific activation of several components of the immune system.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed NSCLC (adenocarcinoma, squamous cell carcinoma, large cell carcinoma, undifferentiated carcinoma or other)
- •Stage IV cancer according to TNM classification (7th edition - UICC, December 2009; includes tumor with malignant pleural or pericardial effusion
- •Tumor biopsy specimen with ≥ 50% of MUC1 expressing tumor cells determined by Immunohistochemistry (IHC) staining on fixed pathological material. Biopsy may come either from the primary tumor or from a metastasis. Cytological material is not accepted for this analysis
- •Patient's naïve to first-line therapy for the advanced stage of the disease. Previous neoadjuvant or adjuvant therapy is allowed for patients who successfully underwent complete radical surgery and if last treatment was administered more than 12 months prior to the start of the study treatment, i.e., D1 of Cycle
- •At least one measurable lesion by CT scan or MRI based on RECIST version 1.1
- •PS 0 or 1 on the ECOG scale
- •Adequate hematological, hepatic, and renal function:
- •Hemoglobin ≥ 10.0 g/dL
- •White Blood Cells (WBC) ≥ 3.0x10E9/L including
- •Neutrophils ≥ 1.5x109/L
- •Total lymphocytes count ≥ 0.5x10E9/L
- •Platelets count ≥ 100x10E9/L
- •Serum alkaline phosphatase ≤ 3x ULN (upper limit of normal)in the absence of liver or bone metastases or ≤5 ULN(in patients with documented bone or liver metastases)
- •Serum transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) ≤ 2.5 x ULN in the absence of liver metastases or =< 5 ULN in case of liver metastases)
- •Total bilirubin ≤1.5 x ULN
- •Glomerular Filtration Rate ≥ 60 mL/min (according to Modification of the Diet in Renal Disease (MDRD) formula or cockroft & Gault formula)
- •Serum albumin ≥ 30 g/L
- •Effective contraception during the study period and for 3 months after the last study treatment administration (male and female patient)
排除标准
- •Patients having Central Nervous System (CNS) metastases. Patients who have had brain metastases surgically removed or irradiated with no residual disease confirmed by imaging are allowed
- •Documented EGFR activating mutations (if already tested)
- •Prior history of other malignancy except:
- •Basal cell carcinoma of the skin
- •Cervical intra epithelial neoplasia
- •Other cancer curatively treated with no evidence of disease for at least 5 years
- •Patients under chronic treatment with systemic corticoids or other immunosuppressive drugs (e.g., cyclosporine) for a period of at least 4 weeks and whose treatment was not stopped 1 week prior to the start of the study treatment (i.e., D1 of Cycle 1)
- •Positive serology for Human Immunodeficiency Virus (HIV) or Hepatitis C Virus (HCV); presence in the serum of the antigens HBs
- •Patient with any underlying medical condition that the treating physician considers might be aggravated by treatment or which is not controlled (e.g., elevated troponin or creatinine, uncontrolled diabetes)
- •Patient with major surgery or radiotherapy within 4 weeks prior to the start of the study treatment (i.e., D1 of Cycle 1). Prior surgery or radiation therapy aimed at local palliation or attempted local disease control is permitted
- •Patient with an organ allograft
- •Known allergy to eggs, gentamicin or platinum-containing compounds
- •Participation in a clinical study with an investigational product within 4 weeks prior to the start of the study treatment (i.e., D1 of Cycle 1)
- •Patient unable or unwilling to comply with the protocol requirements
- •Pregnancy or lactation
- •Bevacizumab will be allowed for patients with non-squamous carcinoma. Prescribing information must be followed and precautions have to be taken into consideration (e.g., patients having presented a serious hemorrhage or recent hemoptysis should not receive bevacizumab).
研究组 & 干预措施
Arm 1 - TG4010 + first line therapy
Experimental
First-line therapy and maintenance therapy
干预措施: TG4010 (Biological)
Arm 2 : Placebo + first line therapy
Active Comparator
First-line therapy and maintenance therapy
干预措施: placebo (Drug)
结局指标
主要结局
Phase 3: Overall Survival (OS)
时间窗: Approximately 27 months
OS is measured from date of randomization to date of death from any cause.
Phase 2: Progression-free Survival (PFS)
时间窗: Approximately 15 months
PFS is measured from date of randomization to radiographically documented progression according to RECIST 1.1 or death from any cause (whichever occurs first). Participants alive and without disease progression or lost to follow-up will be censored at the date of their last radiographic assessment.
次要结局
- Phase 2 : Overall Survival (OS)(Approximately 15 months)
- Phase 2 : Overall Response Rate (ORR)(Approximately 15 months)
- Phase 3: Progression-free Survival (PFS)(Approximately 27 months)
- Phase 2: Safety(Approximately 15 months)
- Phase 3: Duration of response(Approximately 27 months)
- Phase 3 : Overall Response Rate (ORR)(Approximately 27 months)
- Phase 3: Safety(Approximately 27 months)
- Phase 2 : Duration of response(Approximately 15 months)
研究者
研究点 (72)
Loading locations...
相似试验
招募中
2 期
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic MastocytosisNCT04910685Blueprint Medicines Corporation534
Unknown
2 期
To Evaluate SSD8432/Ritonavir in Adults With COVID-19COVID-19NCT05373433Jiangsu Simcere Pharmaceutical Co., Ltd.670
招募中
2 期
Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)COVID-19NCT05445934Frontier Biotechnologies Inc.1,188
尚未招募
2 期
Efficacy and Safety of DT01 Tablets in Patients With Irritable Bowel Syndrome With DiarrheaIrritable Bowel Syndrome With DiarrheaNCT05719896Centre of Clinical Pharmacology, Hanoi Medical University120
进行中（未招募）
2 期
(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic MastocytosisIndolent Systemic MastocytosisNCT03731260Blueprint Medicines Corporation251